Vesigen has attracted Leaps by Bayer to commercialise drug delivery technology invented by Quan Lu at Harvard School of Public Health.

GV had led an oversubscribed series D round for the gene therapy developer that also featured Illumina Ventures and SoftBank Vision Fund II.

Pfizer and Chiesi-backed genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.

Leaps by Bayer has co-led a $28.5m series A round disclosed when precision medicine startup Vesigen Therapeutics publicly launched.

Delta Dental Washington Seed Fund was among the participants in a $10.8m round for the pelvic bone implant developer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the Basel spinout.

The CNS disease therapy developer raised a further $20m, adding to a $45m close in April that included GV and Takeda Ventures.

UPMC Enterprises has contributed to a $20m series B extension for Cerevance, which is commercialising Rockefeller University research.

Septwolves Ventures participated in a $21.5m round for the X-ray equipment producer that was led by a China Construction Bank fund.